Lifejoint develops a next‑generation small joint replacement for finger arthritis that can be inserted easily and predictably, delivering durable pain relief while preserving joint motion. The implant uses advanced materials and geometry to avoid the squeaking, dislocation, and collateral weakness of existing pyrocarbon and silicone devices. It is targeted at hand surgeons and orthopedic specialists treating osteoarthritis, rheumatoid arthritis, and post‑traumatic hand arthritis.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of Americans suffer from symptomatic hand arthritis, but most cannot benefit from existing joint replacement options because the devices are unpredictable, have high failure rates, or limit motion, leaving a large patient population without effective treatment.
Solution
Lifejoint is engineering a next‑generation small joint replacement specifically for the fingers. The device is designed for straightforward surgical insertion and aims to provide reliable pain relief while preserving joint mobility. By using advanced materials and a novel geometry, it seeks to avoid the squeaking, dislocation, and collateral weakness seen in current pyrocarbon and silicone implants. The company integrates rigorous engineering, testing, and regulatory expertise to bring a clinically validated solution to hand surgeons. The goal is to expand treatment options for osteoarthritis, rheumatoid arthritis, and post‑traumatic hand arthritis patients who are currently underserved.
Target Audience
Primary customers are hand surgeons and orthopedic specialists treating patients with advanced hand arthritis who require reliable joint replacement solutions.
Features
- Implant engineered for easy, reproducible insertion in finger joints
- Material selection and surface design that minimize squeaking, dislocation, and collateral plane weakness
- Preserves range of motion while delivering durable pain relief
- Developed with extensive orthopedic device testing and regulatory compliance processes
- Designed for both osteoarthritis, rheumatoid arthritis, and post‑traumatic arthritis indications